An Independent Validation Study of Candidate microRNAs as Predictive Biomarkers for Bevacizumab-based Therapy in Patients With Metastatic Colorectal Cancer

Varování

Publikace nespadá pod Lékařskou fakultu, ale pod Středoevropský technologický institut. Oficiální stránka publikace je na webu muni.cz.

Autoři

KISS David MACHÁČKOVÁ Táňa SOUČKOVÁ Kamila FABIAN Pavel KREPELKOVA I. SVOBODA M. KISS Igor

Rok publikování 2021
Druh Článek v odborném periodiku
Časopis / Zdroj In vivo
Fakulta / Pracoviště MU

Středoevropský technologický institut

Citace
www https://iv.iiarjournals.org/content/35/5/2809
Doi http://dx.doi.org/10.21873/invivo.12567
Klíčová slova Bevacizumab; metastatic colorectal cancer; microRNA; progression-free survival; predictive biomarker; validation
Popis Background/Aim: The monoclonal antibody bevacizumab is a standard drug used in combination with oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) based chemotherapy in the first or second-line treatment of metastatic colorectal cancer (mCRC). Our previous study identified and subsequently validated 4 microRNAs in a small group of patients as predictors of the therapeutic response to bevacizumab combined with chemotherapy. The aim of this follow-up study is to confirm the predictive ability of these tissue miRNAs in a larger independent cohort of mCRC patients. Patients and Methods: The retrospective study included 92 patients with generalized-radically inoperable tumors treated with the combined therapy of bevacizumab/FOLFOX in a standard regimen. Results: Expression levels of candidate miRNA biomarkers (miR-92b3p, miR-3156-5p, miR-10a-5p and miR-125a-5p) were determined in tumor tissue specimens and statistically evaluated. MiR-92b-3p and miR-125a-5p were confirmed to be associated with radiological response according to RECIST criteria (p=0.005 and 0.05, respectively) and to be up-regulated in responders to bevacizumab/FOLFOX therapy. Higher levels of miR-92b-3p were also significantly associated with extended progression-free survival
Související projekty:

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.

Další info